IP Library Granted Patent US 8,911,998
Granted Patent B2
US 8,911,998 · App. 12/739,541 · Granted Dec 16, 2014

Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof

Inventors: Carlo M. Croce (Columbus, OH); Francesco Trapasso (Catanzaro, IT)
Assignee: The Ohio State University
C12N15/86C12N2710/10343A61K38/17G01N33/5011C12Q2600/136G01N2333/90293C12Q1/6886C12Q2600/106
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,911,998
App. No.
12/739,541
Granted
Dec 16, 2014
Kind
B2
Abstract

Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorder using the Fhit gene.

Claims (9)

1. A method for inducing an apoptosis process in a cell, comprising

exposing the cell to an exogenous fragile histidine triad (Fhit) gene product in an amount sufficient to cause generation of reactive oxygen species (ROS) in the cell; and

administering an oxidative stress to the cell, wherein the oxidative stress comprises peroxide, thereby inducing an apoptotic process in the cell.

2. A method for mediating an apoptotic process in at least one cell, comprising:

exposing the cell to a sufficient amount of an exogenous fragile histidine triad (Fhit) gene product to allow the Fhit to enter mitochondria in the cell and to interact with Fdxr protein in the cell, whereby the Fdxr resists proteosomal degradation and accumulates in the cell, thereby causing an increase in Fdxr protein level that is associated with generation of ROS, and

applying an oxidative stress to the cell, wherein the oxidative stress comprises peroxide, causing a change in the apoptotic process in the cell.

3. The method of claim 1 , further comprising:

administering at least one chemotherapeutic agent.

4. The method of claim 3 , wherein the at least one chemotherapeutic agent is selected from the group consisting of: paclitaxel and cisplatin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2011
From: CROCE, CARLO M.; TRAPASSO, FRANCESCO
To: THE OHIO STATE UNIVERSITY
Reel/Frame 025866/0871 →
CONFIRMATORY LICENSE Recorded Oct 18, 2010
From: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025149/0570 →
Continuity (2)
Provisional Application 61000480 · Oct 26, 2007
Related Publication 20120010092A1 · Jan 12, 2012